Patent US5486359A successfully refreshed from Google Patents.
US5486359A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Human mesenchymal stem cells
Assignee: Mesoblast International SARL
•
Filing: 1994-02-08
•
Granted: 1996-01-23
•
Expires: 2014-02-08
Abstract
Abstract Isolated human mesenchymal stem cells which can differentiate into more than one tissue type (e.g. bone, cartilage, muscle or marrow stroma), a method for isolating, purifying, and culturally expanding human mesenchymal stem cells (i.e. "mesenchymal stem cells" or "hMSCs"), and characterization of and uses, particularly research reagent, diagnostic and therapeutic uses for such cells. The stem cells can be culture expanded without differentiating. Monoclonal antibodies specific for human mesenchymal stem cells and the monoclonal hybridoma cell lines (ATCC nos. 10743-10745) that synthesize and secrete these monospecific antibodies, and uses of the monoclonal antibodies for diagnostic and/or therapeutic purposes.
Inventors
- 👤 Arnold I. Caplan
- 👤 Stephen E. Haynesworth
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 19:41
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/36; A61L27/38; A61L27/3804; A61L27/3834; A61F; A61F2/00; A61F2/02; A61F2/28; A61K; A61K35/00; A61K35/12; A61K35/28; A61L27/3839; A61L27/3843; A61L31/00; A61L31/005; C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C12; C12N; C12N5/00; C12N5/0068; C12N5/06; C12N5/0602; C12N5/0652; C12N5/0662; C12N5/0663; A61F2/30; A61F2/30756; A61K2035/124; A61L2430/00; A61L2430/10; C12N2501/00; C12N2501/20; C12N2501/23; C12N2501/30; C12N2501/38; C12N2501/39; C12N2533/00; C12N2533/10; C12N2533/18
Claims Analysis
Total Claims: 39
Claim 1
Independent Claim
21 words
An isolated, homogeneous population of human mesenchymal stem cells which can differentiate into cells of more than one connective tissue type.
Claim 2
Dependent Claim
21 words
An isolated, homogeneous population of human mesenchymal stem cells which can differentiate into cells of more than one connective tissue type.
Claim 3
Dependent Claim
27 words
The mesenchymal stem cells of claim 1 wherein an antibody produced from hybridoma cell line SH2, ATCC accession number HB 10743, binds to said mesenchymal stem cells.
Claim 4
Dependent Claim
17 words
The mesenchymal stem cells of claim 2 wherein said mesenchymal stem cells are obtained from bone marrow.
Claim 5
Dependent Claim
27 words
The mesenchymal stem cells of claim 3 wherein said mesenchymal stem cells adhere to a plastic surface when cultured in BGJ b medium containing 10% fetal serum.
Claim 6
Dependent Claim
29 words
The mesenchymal stem cells of claim 3 wherein said mesenchymal stem cells retain the potential to differentiate into more than one connective tissue type after population expansion in culture.
Claim 7
Dependent Claim
27 words
The mesenchymal stem cells of claim 1 wherein an antibody produced from hybridoma cell line SH3, ATCC accession number HB 10744, binds to said mesenchymal stem cells.
Claim 8
Dependent Claim
27 words
The mesenchymal stem cells of claim 1 wherein an antibody produced from hybridoma cell line SH4, ATCC accession number HB 10745, binds to said mesenchymal stem cells.
Claim 9
Dependent Claim
17 words
The mesenchymal stem cells of claim 1 wherein said mesenchymal stem cells are obtained from bone marrow.
Claim 10
Dependent Claim
27 words
The mesenchymal stem cells of claim 8 wherein said mesenchymal stem cells adhere to a plastic surface when cultured in BGJ b medium containing 10% fetal serum.
Claim 11
Dependent Claim
15 words
The mesenchymal stem cells of claim 1 wherein said mesenchymal stem cells are non-embryonic cells.
Claim 12
Dependent Claim
27 words
The mesenchymal stem cells of claim 1 wherein said mesenchymal stem cells adhere to a plastic surface when cultured in BGJ b medium containing 10% fetal serum.
Claim 13
Dependent Claim
29 words
The mesenchymal stem cells of claim 1 wherein said mesenchymal stem cells retain the potential to differentiate into more than one connective tissue type after population expansion in culture.
Claim 14
Dependent Claim
16 words
The mesenchymal stem cells of claim 1 wherein said mesenchymal stem cells are obtained from periosteum.
Claim 15
Dependent Claim
16 words
The mesenchymal stem cells of claim 1 wherein one of said connective tissue types is bone.
Claim 16
Dependent Claim
16 words
The mesenchymal stem cells of claim 1 wherein one of said connective tissue types is cartilage.
Claim 17
Dependent Claim
16 words
The mesenchymal stem cells of claim 1 wherein one of said connective tissue types is adipose.
Claim 18
Dependent Claim
16 words
The mesenchymal stem cells of claim 1 wherein one of said connective tissue types is tendon.
Claim 19
Dependent Claim
16 words
The mesenchymal stem cells of claim 1 wherein one of said connective tissue types is ligament.
Claim 20
Dependent Claim
16 words
The mesenchymal stem cells of claim 1 wherein one of said connective tissue types is dermis.
Claim 21
Dependent Claim
23 words
A composition comprising the mesenchymal stem cells of claim 1 and a culture medium, wherein said culture medium expands said mesenchymal stem cells.
Claim 22
Dependent Claim
12 words
The composition of claim 20 wherein said medium is a complete medium.
Claim 23
Dependent Claim
12 words
The composition of claim 21 wherein said medium comprises BGJ b medium.
Claim 24
Dependent Claim
23 words
A composition comprising the mesenchymal stem cells of claim 2 and a culture medium, wherein said culture medium expands said mesenchymal stem cells.
Claim 25
Dependent Claim
12 words
The composition of claim 23 wherein said medium is a complete medium.
Claim 26
Dependent Claim
12 words
The composition of claim 24 wherein said medium comprises BGJ b medium.
Claim 27
Dependent Claim
23 words
A composition comprising the mesenchymal stem cells of claim 8 and a culture medium, wherein said culture medium expands said mesenchymal stem cells.
Claim 28
Dependent Claim
12 words
The composition of claim 26 wherein said medium is a complete medium.
Claim 29
Dependent Claim
12 words
The composition of claim 27 wherein said medium comprises BGJ b medium.
Claim 30
Dependent Claim
23 words
A composition comprising the mesenchymal stem cells of claim 5 and a culture medium, wherein said culture medium expands said mesenchymal stem cells.
Claim 31
Dependent Claim
12 words
The composition of claim 29 wherein said medium is a complete medium.
Claim 32
Dependent Claim
12 words
The composition of claim 30 wherein said medium comprises BGJ b medium.
Claim 33
Dependent Claim
32 words
A therapeutic composition comprising the mesenchymal stem cells of claim 1 and a pharmaceutically acceptable carrier, wherein said mesenchymal stem cells are present in an amount effective to produce connective tissue cells.
Claim 34
Dependent Claim
32 words
A therapeutic composition comprising the mesenchymal stem cells of claim 2 and a pharmaceutically acceptable carrier, wherein said mesenchymal stem cells are present in an amount effective to produce connective tissue cells.
Claim 35
Dependent Claim
32 words
A therapeutic composition comprising the mesenchymal stem cells of claim 8 and a pharmaceutically acceptable carrier, wherein said mesenchymal stem cells are present in an amount effective to produce connective tissue cells.
Claim 36
Dependent Claim
32 words
A therapeutic composition comprising the mesenchymal stem cells of claim 9 and a pharmaceutically acceptable carrier, wherein said mesenchymal stem cells are present in an amount effective to produce connective tissue cells.
Claim 37
Dependent Claim
32 words
A therapeutic composition comprising the mesenchymal stem cells of claim 11 and a pharmaceutically acceptable carrier, wherein said mesenchymal stem cells are present in an amount effective to produce connective tissue cells.
Claim 38
Dependent Claim
12 words
The therapeutic composition of claim 32 wherein said connective tissue is bone.
Claim 39
Dependent Claim
12 words
The therapeutic composition of claim 32 wherein said connective tissue is cartilage.
References Cited (Backward Citations)
US3968567A
Cited
US4254226A
Cited
US4430760A
Cited
US4642120A
Cited
US4714680B1
Cited
US4714680A
Cited
US4609551A
Cited
US4596574A
Cited
US4721096A
Cited
US4904259A
Cited
US5053050A
Cited
US5197985A
Cited
US5226914A
Cited
US5206023A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-01-22 | 1999-07-24 | 2000-01-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-01-22 | 2003-07-24 | 2004-01-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-01-22 | 2007-07-24 | 2008-01-23 | $7700.00 | Window Closed / Lapsed |